SELLAS Life Sciences Group, Inc. — Director's Dealing 2020

Mar 17, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELLAS Life Sciences Group, Inc. (SLS)
CIK: 0001390478
Period of Report: 2020-03-12

Reporting Person: Burns John Thomas (VP, Finance & Corp Controller)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-12	Common Stock	A	15000	$0.00	Acquired	15000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-03-12	Stock Option (Right to Buy)	$1.89	A	10000	Acquired	2030-03-12	Common Stock (10000)	Direct

Footnotes

F1: The reporting person received an award of 15,000 restricted stock units on March 12, 2020, which shall vest as follows: (i) 50% on meeting the primary endpoint in Phase 3 REGAL study, provided that if such endpoint is met prior to March 12, 2021, such vesting will not occur until March 12, 2021 and (ii) 50% upon approval by the FDA of galinpepimut-S.

F2: One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 12, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.